HC Wainwright & Co. Maintains Buy on vTv Therapeutics, Lowers Price Target to $42
HC Wainwright & Co. analyst Emily Bodnar maintains vTv Therapeutics (NASDAQ:VTVT) with a Buy and lowers the price target from $45 to $42.
Read original at benzingaStocks · News reference
BTIG Maintains Buy on vTv Therapeutics, Raises Price Target to $57
BTIG analyst Kambiz Yazdi maintains vTv Therapeutics (NASDAQ:VTVT) with a Buy and raises the price target from $49 to $57.
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Jul 16, 2026, 9:46 AM
- Checked
- Jul 16, 2026, 9:46 AM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
vTv Therapeutics Q2 EPS $(1.05) Misses $(0.99) Estimate
vTv Therapeutics (NASDAQ:VTVT) reported quarterly losses of $(1.05) per share which missed the analyst consensus estimate of $(0.99) by 6.06 percent. This is a 14.13 percent decrease over losses of $(0.92) per share
Read original at benzingaAbbott To Rally More Than 35%? Here Are 10 Top Analyst Forecasts For Friday
Recent analyst rating changes, top names such as PPG, SAH, ISRG, MMM, OKE, GLDG, ABT, NFLX, TSCO, and SBAC were upgraded or downgraded.
Read original at benzingaBlackRock To Rally Around 25%? Here Are 10 Top Analyst Forecasts For Thursday
Top Wall Street analysts changed their outlook on top names. See all changes, including upgrades and downgrades, on our analyst ratings page.
Read original at benzinga